AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered, structured, and analyzed by LLMs. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
NVIDIA GTC 2026: Agentic AI Reaches Inflection Point in Healthcare and Life Sciences
At GTC 2026, NVIDIA showcased how agentic AI systems — autonomous agents that coordinate across tasks — are reaching a tipping point in healthcare, from surgical robotics to drug discovery pipelines.
Epic Expands Its AI Road Map as the EHR Becomes the Main Platform Battle
At HIMSS 2026, Epic previewed a wider AI roadmap spanning clinical, patient-facing and operational workflows, while also citing adoption and outcome metrics for built-in features. The development signals that the EHR is evolving from a record system into the control layer for enterprise healthcare AI.
Australian Entrepreneur Uses AI and AlphaFold to Create First Bespoke Cancer Vaccine for a Dog
Sydney tech entrepreneur Paul Conyngham used ChatGPT and Google DeepMind's AlphaFold to help design a personalized mRNA cancer vaccine for his dog Rosie after conventional treatments failed. Working with UNSW researchers, the vaccine was created in under two months and significantly shrank most of Rosie's tumors.
Doctors Are Using AI Far More Often, but Mostly for Documentation and Knowledge Summaries
New AMA survey results reported by Fierce Healthcare show physician use of AI has more than doubled since 2023, reaching 81% in a professional context by 2026. The growth is being driven less by autonomous diagnosis than by documentation and research summarization, revealing where AI is actually gaining traction in care settings.
Intermountain Pushes a New EHR Playbook for AI: Standardize First, Scale Second
At HIMSS 2026, Intermountain Health argued that the key to scaling healthcare AI is not simply deploying models but building a standardized cloud data layer from EHR systems. The story underscores a growing industry view that interoperability and data normalization are now the limiting factors for AI value in care delivery.
FDA Grants Breakthrough Device Status to Generative AI Chatbot for Surgical Recovery
The FDA has granted breakthrough device designation to RecovryAI, an LLM-based chatbot for patients recovering from joint replacement surgery. It marks the first time a generative AI tool has received this designation, signaling how the agency plans to regulate clinical chatbots.
AI Cracks the Rare-Disease Diagnostic Odyssey
A new Nature-backed advance spotlights DeepRare, an AI system designed to generate ranked rare-disease diagnoses by combining clinical data, genetic information and literature evidence. The story matters because rare-disease diagnosis is one of medicine’s longest-standing bottlenecks, and explainable ranking could make AI more usable in specialist workflows.
AI in Drug Discovery: 2025 in Review — Insilico Medicine Hits Phase IIa Milestone
Insilico Medicine achieved the first positive Phase IIa results for a fully AI-designed drug, while the Recursion-Exscientia merger created an end-to-end AI drug discovery platform. Over 200 AI-discovered drugs are now in development.
Predictive Medicine Moves Closer as AI Models Forecast More Than 1,000 Diseases
Nature Biotechnology reports that AI tools are increasingly able to use clinical records and current health data to predict disease onset and treatment outcomes across a vast number of conditions. The shift reframes AI in healthcare from reactive support toward earlier risk stratification and preventive care.
EU Clarifies That High-Risk AI Rules Will Hit Many Medical Devices Later Than 2026
Updated European Commission guidance on the AI Act makes clear that many AI systems embedded in regulated products such as medical devices are classified as high-risk, but their specific obligations are set to apply from August 2, 2027. The timing matters for manufacturers trying to map MDR, product liability and AI Act requirements into one compliance strategy.
FDA Clears eMurmur’s New AI Heart-Murmur Detection Software
eMurmur received FDA 510(k) clearance for eMurmur Heart AI (2.2), a next-generation heart-murmur detection platform designed for use with digital stethoscopes. The authorization is a concrete reminder that AI device innovation is spreading beyond radiology into frontline physical-exam workflows.
EU AI Act: New Compliance Guidelines for Medical Device Manufacturers Take Shape
As the EU AI Act's high-risk requirements approach their August 2026 enforcement date, detailed guidelines for medical device manufacturers clarify how AI Act obligations interact with existing EU MDR requirements.
Going Founder Mode on Cancer: How GitLab's CEO Used AI and Genomics to Fight Osteosarcoma
GitLab CEO Sid Sijbrandij applied his engineering mindset to his own osteosarcoma diagnosis, assembling a team that used single-cell sequencing, AI-guided therapy selection, and experimental treatments to achieve remission after standard oncology protocols failed.
Illumina CEO: 2026 Is a Turning Point for Precision Health
Illumina CEO Jacob Thaysen declared 2026 a transformative year for precision health, unveiling the AI-powered Billion Cell Atlas for disease pathway mapping in partnership with AstraZeneca, Eli Lilly, and Merck, alongside full multiomics integration by year-end.
FDA Reduces Oversight of AI Health Software and Wearables, Clarifying Low-Risk Categories
The FDA published guidance in January 2026 that reduces regulatory oversight of certain AI-enabled health software and consumer wearables, clarifying that many low-risk tools fall outside medical device regulation when clinicians can independently review recommendations.
Stanford's SleepFM Predicts Over 100 Disease Risks from a Single Night's Sleep Data
Stanford Medicine researchers developed SleepFM, an AI model trained on nearly 600,000 hours of sleep data that can predict a person's risk for over 100 health conditions — including Parkinson's, dementia, and cancers — from one night of polysomnography.
How Multi-Agent AI Systems Are Improving Clinical Decision Support at BJC Healthcare
BJC Healthcare is deploying coordinated teams of AI agents that go beyond simple chatbots to pull data, triage patients, and nudge clinicians at the right time — including a learning reviewer that continuously adapts from 35,000+ patient records.
AI Drug Discovery Reaches 173 Active Clinical Programs With New FDA Framework
A comprehensive analysis counts 173 active AI-discovered drug programs in clinical development, supported by an evolving FDA framework for credibility assessment of AI models used in drug discovery.
2025 Year in Review: 295 AI/ML Medical Device Clearances Set New Record
The FDA cleared 295 AI/ML-enabled medical devices in 2025, bringing the cumulative total past 1,200. Radiology continues to dominate, but cardiology and pathology AI tools are growing rapidly.
In Radiology, AI Is Advancing Faster Than the Field Can Keep Up
With over 1,000 FDA-cleared AI tools now available in radiology, RSNA 2025 showcased AI moving from flashy demos into day-to-day clinical reality. But adoption, integration, and workflow challenges remain significant hurdles.
Five Years On, AlphaFold Shows Why Science May Be AI's Killer App
Five years after its debut, Google DeepMind's AlphaFold has been used by over 3 million researchers in 190+ countries. Fortune examines how it has become AI's most impactful real-world application in science and healthcare.
UCLA Study Finds AI Ambient Scribes Reduce Documentation Time and Improve Physician Well-Being
A randomized clinical trial at UCLA compared two ambient AI scribe systems and found meaningful reductions in documentation time per note and improvements in physician burnout measures, though AI-generated notes occasionally contained clinically significant inaccuracies.
Northwestern's Generative AI System Drafts Personalized Radiology Reports in Real Time
Northwestern Medicine researchers developed a first-of-its-kind generative AI that analyzes medical imaging and drafts personalized radiology reports in real time, boosting radiologist productivity by up to 40%.
The First Trial of Generative AI Therapy Shows It Might Help With Depression
MIT Technology Review examines the Dartmouth Therabot trial — the first rigorous test of generative AI for mental health treatment — and what its promising results mean for the future of therapy access.
First Randomized Trial of Generative AI Therapy Chatbot Shows Significant Mental Health Benefits
Dartmouth researchers conducted the first-ever randomized controlled trial of a generative AI therapy chatbot called Therabot. Participants with depression saw a 51% reduction in symptoms, while those with anxiety experienced a 31% reduction over four weeks.
Google DeepMind CEO Says AI-Designed Drugs Are Entering Clinical Trials
Demis Hassabis announced that pharmaceutical drugs designed by AI at Isomorphic Labs are entering clinical trials, marking a new chapter in AlphaFold's journey from protein structure prediction to active drug design.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
Claude analyzes each source, extracts key information, and produces structured articles with categories, tags, and analytical context.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.